OPRX OptimizeRx Corporation

As filed with the Securities and Exchange Commission on June 18, 2024

Commission File No. 333-             

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

 

Nevada		26-1265381
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
260 Charles Street, Suite 302, Waltham, MA		02453
(Address of Principal Executive Offices)		(Zip Code)

 

OptimizeRx Corporation

2021 Equity Incentive Plan

(Full title of the plan)

 

Marion Odence-Ford, Esquire

General Counsel

OptimizeRx Corporation

260 Charles Street

Suite 302

Waltham, MA 02453

(248) 651-6568

(Name and address of agent for service)

(Telephone number, including area code, of agent for service)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.      ☐

 

 

 

REGISTRATION OF ADDITIONAL SHARES

PURSUANT TO GENERAL INSTRUCTION E

 

Pursuant to General Instruction E of Form S-8, the Registrant hereby makes the following statement: This Registration Statement on Form S-8 is being filed by the Registrant to register an additional 1,950,000 shares of its common stock which, pursuant to an amendment to the Registrant’s 2021 Equity Incentive Plan (the “Plan”), are issuable upon the grant, exercise or vesting of awards under the Plan. These 1,950,000 shares are in addition to the 2,500,000 shares of the Registrant’s common stock which were previously registered pursuant to the Registrant’s Registration Statement on Form S-8 (Commission File No. 333-259218) filed with the Securities and Exchange Commission (the “Commission”) on August 31, 2021 (the “Prior Registration Statement”). Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference.

 

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The following documents, as filed with the Commission, are incorporated by reference into this Registration Statement by the Registrant:

 

(a)

the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on April 15, 2024  (including information specifically incorporated by reference therein from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed on April 29, 2024);

 

(b)

the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 15, 2024;

 

(c)

the Registrant’s Current Reports on Form 8-K filed on January 5, 2024, January 26, 2024, April 2, 2024 (solely with respect to Item 1.01) and June 7, 2024.

 

(d)

the description of the Registrant’s Common Stock contained in the Registrant’s Current Report on Form 8-K filed on August 31, 2021.

 

All documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part of this Registration Statement from the date of the filing of such documents.

 

To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, is or was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

 

 

Item 8. Exhibits.

 

The following exhibits are filed as part of this Registration Statement or, where so indicated have been previously filed and are incorporated herein by reference.

 

Exhibit		Description of Exhibit
4.1		Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-1, as filed with the Commission on November 12, 2008).
4.2		Certificate of Correction of the Registrant, dated April 30, 2018 (incorporated by reference to Exhibit 3.5 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the Commission on March 12, 2019).
4.3		Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Commission on March 10, 2023).
4.4		OptimizeRx Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on August 25, 2021).
4.5		Amendment No. 1 to the OptimizeRx 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on June 7, 2024).
5.1		Opinion of The Doney Law Firm.
23.1		Consent of UHY LLP.
23.2		Consent of The Doney Law Firm (included in Exhibit 5.1).
24.1		Power of Attorney (included on the signature page of this Registration Statement).
107.1		Filing Fee table.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts on June 18, 2024.

 

	OptimizeRx Corporation
	By:	/s/ William J. Febbo
	Name:	William J. Febbo
	Title:	Chief Executive Officer

 

POWER OF ATTORNEY

 

We, the undersigned officers and directors of OptimizeRx Corporation, hereby severally constitute and appoint William Febbo and Edward Stelmakh, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

 

Signature		Title		Date
/s/ William J. Febbo		Chief Executive Officer and Director		June 18, 2024
William J. Febbo		(Principal Executive Officer)
/s/ Edward Stelmakh		Chief Financial Officer and Chief Operations Officer		June 18, 2024
Edward Stelmakh		(Principal Financial and Accounting Officer)
/s/ Lynn O’Connor Vos		Director, Chairperson		June 18, 2024
Lynn O’Connor Vos
/s/ James Lang		Director		June 18, 2024
James Lang
/s/ Patrick Spangler		Director		June 18, 2024
Patrick Spangler
/s/ Gregory D. Wasson		Director		June 18, 2024
Gregory D. Wasson
/s/ Catherine M. Klema		Director		June 18, 2024
Catherine M. Klema

 

 

II-3

Exhibit 5.1

 

 

June 18, 2024

 

OptimizeRx Corporation

260 Charles Street, Suite 302

Waltham, MA 02453

 

Re:        OptimizeRx Corp., Registration Statement on Form S-8

 

Ladies and Gentlemen:

 

We have acted as counsel for OptimizeRx Corporation, a Nevada corporation (the “Company”), in connection with the preparation of the registration statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended (the “Act”), relating to the registration of an additional 1,950,000 shares of the Company’s common stock (the “Shares”), which may be issued pursuant to the Company’s 2021 Equity Incentive Plan (the “Plan”).

 

In rendering the opinion set forth below, we have reviewed: (a) the Registration Statement and the exhibits attached thereto; (b) the Company’s Articles of Incorporation, as amended; (c) the Company’s Bylaws, as amended; (d) certain records of the Company’s corporate proceedings as reflected in its minute books including resolutions of the board of directors approving the Plan; (e) the Plan; and (f) such statutes, records and other documents as we have deemed relevant. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and conformity with the originals of all documents submitted to us as copies thereof.

 

Based upon the foregoing, we are of the opinion that the Shares have been validly authorized, and when the Registration Statement has become effective under the Act, such Shares will, when issued pursuant to the terms of the Plan, be legally issued, fully paid and non-assessable shares of the Company’s common stock.

 

Very truly yours,
The Doney Law Firm
/s/ Scott Doney
Scott Doney, Esq.

 

 

OptimizeRx Corp.

June 18, 2024

Page 2

 

CONSENT

 

WE HEREBY CONSENT to the inclusion of our name and use of our opinion in connection with the Form S-8 Registration Statement filed with the Securities and Exchange Commission as counsel for the registrant, OptimizeRx Corporation.

 

Very truly yours,
The Doney Law Firm
/s/ Scott P. Doney
Scott P. Doney, Esq

 

 

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in this Registration Statement of OptimizeRx Corporation on Form S-8 our report dated April 15, 2024, with respect to our audit of the consolidated financial statements of OptimizeRx Corporation and Subsidiaries as of December 31, 2023 and 2022 and for the years then ended appearing in the Annual Report on Form 10-K of OptimizeRx Corporation and Subsidiaries for the year ended December 31, 2023.

 

/s/ UHY LLP
Sterling Heights, Michigan
June 18, 2024

 

 

Exhibit 107.1

 

Calculation of Filing Fee Table

 

Form S-8

(Form Type)

 

OptimizeRx Corporation

(Exact Name of Registrant as Specified in its Charter)

 

Newly Registered Securities 

 

Security Type		Security Class Title		Fee Calculation Rule		Amount Registered(1)				Proposed Maximum Offering Price Per Unit(2)				Maximum Aggregate Offering Price				Fee Rate				Amount of Registration Fee
Equity		Common stock, par value $0.001 per share (“Common Stock”)		Rule 457(c) and Rule 457(h)			1,950,000			$	10.94			$	21,333,000			$	0.00014760			$	3,148.7508
Total Offering Amounts														$	21,333,000							$	3,148.7508
Total Fee Offsets																							—
Net Fee Due																						$	3,148.7508

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (“Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration that results in an increase in the number of the outstanding shares of the Registrant’s Common Stock.

(2)

Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based on the average of the high and low prices of the Registrant’s Common Stock as reported on the Nasdaq Capital Market on June 17, 2024.

 

 

---